Skip to content
Peptigraph home
Shop Peptides50% off*

How long has retatrutide been around?

Retatrutide, known in early papers as LY3437943, entered human multiple-dose testing in a phase 1b trial that enrolled people with type 2 diabetes between Dec 18, 2019, and Dec 28, 2020.

GLP-1 / GIP / glucagon triple agonistUpdated

Short answer

Retatrutide, known in early papers as LY3437943, entered human multiple-dose testing in a phase 1b trial that enrolled people with type 2 diabetes between Dec 18, 2019, and Dec 28, 2020.[1]

From first trials to phase 3

That phase 1b study ran 12 weeks of weekly injections and was designed first to assess safety and tolerability.[1]

A phase 2 trial in adults with obesity then treated participants once weekly for 48 weeks.[2]

The first phase 3 result, TRIUMPH-1 in adults with obesity, appeared online in the New England Journal of Medicine on 2026 Sep 29.[3]

Despite these years of trials, Drugs@FDA returns no match for retatrutide, so no approved product exists in that database.[4]

More questions on Retatrutide

Can retatrutide cause cancer?Can retatrutide cause high blood pressure?Can retatrutide cause joint pain?Can retatrutide cause pancreatitis?Can women take retatrutide?Can you build muscle on retatrutide?

More on Retatrutide

Retatrutide overview

Sources

  1. 1LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
  2. 2Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
  3. 3pubmed.ncbi.nlm.nih.gov pagePubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  4. 4Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.